miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2
5-Fluorouracil (5FU)-based adjuvant therapy is the first-line therapy for treating stage II and III colon cancer after surgery. However, its therapeutic efficacy is limited because of chemoresistance, especially in deficient mismatch repair (dMMR) colon cancer. Here, we first used laser capture micr...
I tiakina i:
Ngā kaituhi matua: | , , , , , , , , , |
---|---|
Hōputu: | Pukapuka |
I whakaputaina: |
Elsevier,
2017-06-01T00:00:00Z.
|
Ngā marau: | |
Urunga tuihono: | Connect to this object online. |
Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ipurangi
Connect to this object online.3rd Floor Main Library
Tau karanga: |
A1234.567 |
---|---|
Tārua 1 | Wātea |